Evidence map›Paper›PMID 42166060›Full record

ArticleAnnals of surgical oncology2026

ASO Special Article: Proceedings of the Inaugural Joint US-India Cancer Dialogue: Accelerating Collaboration to Advance Cancer Prevention, Early Detection, Treatment, and Care.

Catharine Young, Dhananjay Tiwary, Maria Ekstrand, Harmala Gupta, Sudeep Gupta, Anuj Kapadia, Somesh Kumar, Umesh Mahantshetty, Sanjay Kumar Mishra, Padmanee Sharma and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Catharine YoungHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Dhananjay TiwaryDepartment of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi, India.
Maria EkstrandUniversity of California, San Francisco, San Francisco, CA, USA.
Harmala GuptaCancer Care India and CanSupport, Chandigarh, India.
Sudeep GuptaTata Memorial Centre, Mumbai, India.
Anuj KapadiaOak Ridge National Laboratory, Oak Ridge, TN, USA.
Somesh Kumar, Jhpiego, Baltimore, MD, USA.
Umesh MahantshettyHomi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, India.
Sanjay Kumar MishraDepartment of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi, India.
Padmanee SharmaMD Anderson Cancer Center, Houston, TX, USA.
Aparna ParikhMassachusetts General Hospital, Boston, MA, USA.
T RajkumarAdyar Cancer Institute, Chennai, India.
Sagar SenguptaNational Institute of Biomedical Genomics (NIBMG), Kolkata, India.
Shalini SinghIndian Council of Medical Research (ICMR)-National Institute of Cancer Prevention Research (NICPR), Noida, India.
Niloo SrivastavaDepartment of Biotechnology, Ministry of Science and Technology, Government of India, New Delhi, India.
Alok ThakarNational Cancer Institute (NCI)-All India Institute of Medical Sciences (AIIMS), New Delhi, India.
Srinivasan YegnasubramanianJohns Hopkins School of Medicine, Baltimore, MD, USA.
Saumya VarmaUniversity of California, San Francisco, San Francisco, CA, USA.
Camilla WhiteDGA Group, Washington, DC, USA.
Chandrakanth AreUniversity of Nebraska Medical Center, Omaha, NE, USA. care@unmc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer is a leading cause of death in both the USA and India. During Prime Minister Narendra Modi's State Visit to Washington, DC in June 2023, the two governments announced several cooperation commitments. One such commitment was the establishment of the US-India Cancer Dialogue, initiating a structured bilateral effort to address shared cancer challenges. The aim of this article is to outline the preparatory steps and proceedings of the inaugural joint meeting of the US-India Cancer dialogue that took place in New Delhi in August 2024. MATERIALS AND

methodsThis manuscript reports the outcomes of a structured bilateral consensus development process designed to identify priority areas for collaboration between the USA and India. Following the announcement, a high-level virtual consultation convened government, scientific, and clinical leaders to identify shared priority areas. A US-based meeting hosted by the American Society of Clinical Oncology (ASCO) refined technical workstreams, including prevention, early detection, therapeutics, clinical trials, and implementation science. Continued coordination among the US National Cancer Institute, the White House Office of Science and Technology Policy, and India's Department of Biotechnology formalized the bilateral agenda

resultsOver 2 days, the in-person Dialogue identified priority areas for bilateral collaboration, including expansion of human papillomavirus (HPV) vaccination and cervical cancer screening, advancement of artificial intelligence (AI)-enabled early detection technologies, improved access to immunotherapies and chimeric antigen receptor T cell (CAR-T) therapies, strengthened genomics and data-sharing infrastructure, expanded clinical trial capacity, and enhanced survivorship and palliative care.

conclusionsThis collaboration establishes a durable framework to accelerate innovation, expand equitable access, and reduce preventable cancer deaths across both nations.

Indexed as

Early Detection of CancerInternational CooperationNeoplasmsHumansIndiaUnited StatesCancer careCancer moonshotUS–India cancer dialogue

Identifiers

PMID42166060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.